Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Fortune who wrote (10148)	5/10/1999 3:03:00 PM
From: Tomstocks	Read Replies (1) \| Respond to of 13776

News Just Out on ADGI! Volume & Price are moving nicely! ADGI Announces Sales of Dengue Fever Test Kit to Brazil May 10, 1999 02:07 PM HICKORY, N.C.--(BUSINESS WIRE)--May 10, 1999--American Diversified Group ADGI today announced that through its Brazilian representatives, sales of the dengue fever test kit have commenced in Brazil. ADGI had previously announced its efforts necessary to secure sales approvals of the US manufactured dengue fever test kit. As a result of the efforts of ADGI's Brazilian representatives, approval of the sale of the dengue fever test kit have been received. The initial order is for 2000 test kits, and shipment started during the week of May 3, 1999. The first shipment is to the Brazilian State of Roraima, and additional sales to other Brazilian States shall follow. The sales of the dengue fever test kits, which are profitable for ADGI, are the orders for the dengue fever test kits that ADGI has been pursuing for approximately one year. ADGI's president, Dr. Jerrold R. Hinton, believes that the orders and sales of the dengue fever test kits in Brazil will be both continuing and increasing during fiscal 1999. The recent sales began with the start of the 1999 Brazilian rainy season. During 1997 and 1998, the rainy season in Brazil resulted in a rise of dengue fever that Brazilian and World Health authorities considered to be of epidemic proportion. Dengue fever tests are constantly repeated on persons living in or near epidemic areas to properly track the disease and promote treatment in the required areas. Executive Offices: 110 N. Center St., Suite 202, Hickory, NC 28601 828-322-2044 - Fax: 828-322-3798 Investor Relations: 45 Rockefeller Plaza, Suite 2000, NY, NY 10111 212-332-5009 - Fax: 212-332-3249 Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect," "should," "would," and similar expressions and all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financing or operating) or achievements to differ from future results, performance (financing or operating) or achievements expressed or implied by such forward-looking statements. The above factors are more fully discussed in the Company's SEC filings.